Orforglipron , an oral GLP-1 agonist, has shown the ability to maintain weight loss in patients switching from injectable therapies
Therefore, from the maximum dose of 2.4mg, the patient stays on this dose for 4 weeks, then gets reduced to 1.7mg, then 1mg, then 0.5mg, then finally 0.25mg for 4 weeks, and then stops treatment
& Putzier, M
Radiance That Defends Radiance That Defends This duo doesnt just help you glow, it helps protect it
In conclusion, BARI-STEP, a randomized, placebo-controlled trial investigating the use of once-weekly semaglutide 2.4 mg in a post-bariatric patient population with a suboptimal clinical response, demonstrates that semaglutide 2.4 mg in patients with a suboptimal clinical response results in substantial, clinically relevant body weight reduction, and improvements in metabolic health and quality of life
However, no controlled conditions (placebo effects, natural healing, concurrent treatments confound results)